Early vs delayed screening for prostate cancer

Conditions

Prostate cancer Cancer Prostate cancer

Boschheidgen M, Al-Monajjed R, Schlemmer HP, Krilaviciute A, Bonekamp D, Herkommer K, Jahnen M, Gschwend JE, Düx D, Wacker F, Makowski MR, Sauter A, Kuczyk MA, Harke N, Debus J, Grott C, Lakes J, Radtke JP, Arsov C, Seibold P, Hadaschik B, Giesel F, Kristiansen G, Benner A, Antoch G, Becker N, Kaaks R, Albers P, Schimmöller L.

2026-06-01

10.1016/j.euo.2026.05.003

Value of Additional Systematic Cores During Magnetic Resonance Imaging-guided Targeted Biopsy in Prostate Cancer Screening for Young Men: Results from the PROBASE Trial.

Al-Monajjed R, Boschheidgen M, Lakes J, Krilaviciute A, Radtke JP, Schlemmer HP, Bonekamp D, Herkommer K, Jahnen M, Gschwend JE, Düx D, Wacker F, Makowski MR, Sauter A, Kuczyk MA, Harke N, Debus J, Grott C, Arsov C, Seibold P, Benner A, Hadaschik B, Giesel F, Kristiansen G, Antoch G, Becker N, Kaaks R, Albers P, Schimmöller L.

2025-11-10

10.1016/j.euo.2025.10.014

Prostate Cancer Detection in Younger Men: A Comparative Analysis of Systematic and Magnetic Resonance Imaging–targeted Biopsy in the PROBASE Trial

Rouvier Al‐Monajjed, Matthias Boschheidgen, Jale Lakes, Agnė Krilavičiūtė, Jan-Philipp Radtke et al. (28 authors)

European Urology2025-06-026 citations

10.1016/j.eururo.2025.05.020

Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.

Boschheidgen M, Albers P, Schlemmer HP, Hellms S, Bonekamp D, Sauter A, Hadaschik B, Krilaviciute A, Radtke JP, Seibold P, Lakes J, Arsov C, Gschwend JE, Herkommer K, Makowski M, Kuczyk MA, Wacker F, Harke N, Debus J, Körber SA, Benner A, Kristiansen G, Giesel FL, Antoch G, Kaaks R, Becker N, Schimmöller L.

2023-10-1830 citations

10.1016/j.eururo.2023.09.027

Interventions

Men at age 45 years are randomized into two screening groups following a 1:1 distribution for early first PSA (prostate specific antigen) testing at age 45 years (study arm A) versus delayed first PSA

Eligibility

Sex/Gender

Male

Age

45 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Males at age 45 years at the time of consent 2. Willing and able to provide written informed consent 3. Written data protection consent has been obtained 4. Able to adhere to the study visit schedule and requirements of the protocol

Exclusion criteria

Exclusion criteria: Previous history of prostate cancer

Design outcomes

Primary

Measure	Time frame
Incidence of metastatic prostate cancer up to the age of 60 years as judged by imaging and confirmatory biopsy of metastases	—

Secondary

Measure	Time frame
Measured by patient records: 1. Incidence of late metastasis (M+ = radiographically and histologically proven bone metastases and/or radiographically and histologically proven nonregional lymph node or visceral metastases) after curative treatment (radical prostatectomy, radiotherapy) of detected prostate cancers up to the age of 60 years 2. Incidence of biochemical recurrences after curative treatment (radical prostatectomy, radiotherapy) of detected prostate cancers up to the age of 60 years 3. Locally advanced prostate cancers detected up to the age of 60 years 4. Incidence of high-grade prostate cancers detected up to the age of 60 years 5. The prostate cancer mortality rate up to the age of 60 years 6. Overall survival up to the age of 60 years	—

Measure

Time frame

Measured by patient records: 1. Incidence of late metastasis (M+ = radiographically and histologically proven bone metastases and/or radiographically and histologically proven nonregional lymph node or visceral metastases) after curative treatment (radical prostatectomy, radiotherapy) of detected prostate cancers up to the age of 60 years 2. Incidence of biochemical recurrences after curative treatment (radical prostatectomy, radiotherapy) of detected prostate cancers up to the age of 60 years 3. Locally advanced prostate cancers detected up to the age of 60 years 4. Incidence of high-grade prostate cancers detected up to the age of 60 years 5. The prostate cancer mortality rate up to the age of 60 years 6. Overall survival up to the age of 60 years

—

Countries

Germany

Outcome results

None listed